Press release content from PR Newswire. The AP news staff was not involved in its creation.
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA
January 27, 2021 GMT
INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market.
In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in South Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody provided by Eutilex (KOSDAQ:263050). Studied by NOV and Eutilex with humanized mice, EU101(NOV1801), effectively eradicated human tumors and showed synergistic anti-tumor activity with immune checkpoint blockade.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Logi Analytics Announces New Analytics Dashboard Experience for BlueVolt Platform
January 26, 2021 GMT
MCLEAN, Va. (BUSINESS WIRE) Jan 26, 2021
Today, Logi Analytics, the leading provider of embedded analytics solutions for software teams, and BlueVolt, an award-winning authority of online learning solutions for sales and channel marketing, announce a new partnership utilizing Logi Info to create a cutting edge analytics dashboard experience for all BlueVolt customers. With the upcoming BlueVolt analytics dashboard, customers will have better insight than ever before into their channel partner education and training strategies.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Biorasi Welcomes Neurology Professor Dr. Ole Isacson to Scientific Advisory Board
January 26, 2021 GMT
MIAMI (BUSINESS WIRE) Jan 26, 2021
Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the appointment of Ole Isacson, MD, PhD, Professor of Neurology and Neuroscience, to the position of Scientific Advisory Board (SAB) member. In this role, Dr. Isacson will provide leadership and clinical expertise for neurology clinical trials and related areas at Biorasi.
ADVERTISEMENT
“I look forward to working with Dr. Isacson in expanding our knowledge base in neurology, including rare and urgent diseases,” said Jimmy El Hokayem, PhD, Head of the Neurology and Regenerative Medicine Center of Excellence and Associate Director of Program Development at Biorasi. “I genuinely believe that his unique profile as one of today’s prominent clinical l
Press release content from Newswire. The AP news staff was not involved in its creation.
Stem Cell Recruitment Therapy® Registration Awarded by U.S. Patent & Trademark Office for Russell Health
January 27, 2021 GMT
Stem Cell Recruitment Therapy® by Russell Health
WILLOWBROOK, Ill. - January 26, 2021 - ( Newswire.com )
Based in Willowbrook, Illinois, Russell Health, a national marketer and distributor of specialty medical products and services, has recently been issued company trademark registrations from the United States Patent and Trademark Office.
Russell Health, Inc., a leading regenerative medicine company, announced today the United States Patent and Trademark Office has issued registrations for the company’s trademarks - Stem Cell Recruitment Therapy® (Reg. No. 6,109,514) and Stem Cell Recruitment Facial® (Reg. No. 6,218,705), signifying that the company has met the stringent United States standards for exclusively applying its trademarks to the company’s produ